https://scholars.lib.ntu.edu.tw/handle/123456789/194585
標題: | 嚴重急性呼吸道症候群的免疫致病機轉(第二年)─(子計畫四)SARS病人抗上皮細胞及內皮細胞自體抗體致病角色之探討 | 作者: | 楊曜旭 | 關鍵字: | SARS;autoantibodies;epithelial cell;endothelial cell;cytotoxicity | 公開日期: | 2005 | 出版社: | 臺北市:國立臺灣大學醫學院小兒科 | 摘要: | The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, one month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against 1) A549 human pulmonary epithelial cell-line, 2) human umbilical venous endothelial cells (HUVEC), 3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/29839 | 其他識別: | 932751B002006Y | Rights: | 國立臺灣大學醫學院小兒科 |
顯示於: | 醫學系 |
檔案 | 描述 | 大小 | 格式 | |
---|---|---|---|---|
932751B002006Y.pdf | 127.37 kB | Adobe PDF | 檢視/開啟 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。